Grafalon (Anti-T Lymphocyte Immunoglobulin For Human Use, Rabbit)

Grafalon is employed in clinical settings where modulation of the immune response is required. It is commonly used in the following contexts:

• Prevention of acute rejection in organ transplantation, particularly kidney and liver transplants.
• Treatment of severe aplastic anemia as part of conditioning regimens.
• Management of graft‑versus‑host disease (GVHD) following hematopoietic stem cell transplantation.
• Induction therapy for certain autoimmune disorders when other treatments have failed.
• As an adjunct in conditioning protocols prior to bone marrow transplantation.

Side effects of Grafalon vary in frequency and severity. They are typically categorized as follows:

Common

• Fever and chills during or after infusion.
• Nausea, vomiting, or abdominal discomfort.
• Transient hypertension or hypotension.
• Mild rash or urticaria at the infusion site.
• Elevated liver enzymes.
• Fatigue or malaise.

Serious

• Severe allergic reactions including anaphylaxis.
• Cytokine release syndrome with hypotension and respiratory distress.
• Opportunistic infections due to profound immunosuppression.
• Thromboembolic events such as deep‑vein thrombosis.
• Hemolytic anemia or thrombocytopenia.
• Renal impairment or acute kidney injury.

When considering Grafalon, clinicians should observe several precautionary measures. Important considerations include:

• Baseline assessment of infection risk; avoid use in active uncontrolled infections.
• Monitor complete blood counts and liver/kidney function before and during therapy.
• Screen for prior hypersensitivity to rabbit proteins or other immunoglobulin products.
• Use with caution in patients with cardiovascular disease due to possible infusion‑related hemodynamic changes.
• Evaluate for malignancy history, as profound immunosuppression may affect tumor surveillance.
• Ensure appropriate vaccination status; live vaccines are contraindicated during treatment.
• Discuss potential pregnancy and lactation implications with patients, as safety data are limited.

Grafalon may interact with other medications, influencing efficacy or safety. Interactions are generally grouped as:

Avoid

• Concurrent use of other potent immunosuppressants (e.g., alemtuzumab) without dose adjustment, due to additive immunosuppression.
• Live viral vaccines administered during or shortly after therapy.
• High‑dose corticosteroids that may exacerbate infection risk.

Use with caution

• Antimicrobial agents (e.g., antivirals, antifungals) that require dose modification in immunocompromised patients.
• Anticoagulants, as infusion reactions can affect coagulation parameters.
• Cytokine‑targeted therapies that may amplify cytokine release syndrome.
• Drugs metabolized by the liver, given potential hepatic enzyme alterations.